Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DMG Deutsche Malaria
Hamburg, Hamburg, Germanydmg-deutschemalaria.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
DMG Deutsche Malaria has successfully completed a Phase I/IIa clinical study with a non-artemisinin combination drug for uncomplicated falciparum malaria and is preparing to commence clinical trials for a triple drug combination targeting severe malaria. Their most advanced program combines fosmidomycin and piperaquine, which has shown promise in African Phase II studies[6][10].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Medicines for Malaria Venture (MMV)European & Developing Countries Clinical Trials Programme (EDCTP)World Health Organization (WHO)EU Malaria Fund
Beyond the preview
Go deeper on DMG Deutsche Malaria.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMG Deutsche Malaria.